BioVaxys Technology Corp. (BVAXF)
USD 0.02
(-5.22%)
USD 0.02
(-5.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | - CAD | -247.63% |
| 2022 | 3.57 Million CAD | 155.77% |
| 2021 | - CAD | -486.69% |
| 2020 | - CAD | -376.29% |
| 2019 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -370.7 Thousand CAD | 100.0% |
| 2024 Q2 | -539.19 Thousand CAD | 0.0% |
| 2024 Q3 | - CAD | 0.0% |
| 2023 Q2 | 97.97 Thousand CAD | 111.25% |
| 2023 Q1 | -871.04 Thousand CAD | -113.0% |
| 2023 FY | - CAD | -280.28% |
| 2023 Q4 | -4.19 Million CAD | -1022.91% |
| 2023 Q3 | 454.33 Thousand CAD | 363.75% |
| 2022 Q4 | 6.7 Million CAD | 842.36% |
| 2022 Q3 | -902.89 Thousand CAD | 11.38% |
| 2022 FY | - CAD | 155.77% |
| 2022 Q2 | -1.01 Million CAD | 15.19% |
| 2022 Q1 | -1.2 Million CAD | 52.03% |
| 2021 Q4 | -2.5 Million CAD | -184.12% |
| 2021 FY | - CAD | -486.69% |
| 2021 Q3 | -881.41 Thousand CAD | 41.05% |
| 2021 Q2 | -1.49 Million CAD | 2.77% |
| 2021 Q1 | -1.53 Million CAD | -79.81% |
| 2020 Q3 | -139.8 Thousand CAD | -113.75% |
| 2020 Q1 | -33.6 Thousand CAD | 50.49% |
| 2020 FY | - CAD | -376.29% |
| 2020 Q4 | -855.19 Thousand CAD | -511.7% |
| 2020 Q2 | -65.4 Thousand CAD | -94.62% |
| 2019 Q3 | -37.8 Thousand CAD | 35.45% |
| 2019 Q1 | -65.44 Thousand CAD | 49.77% |
| 2019 FY | - CAD | 0.0% |
| 2019 Q4 | -67.88 Thousand CAD | -79.55% |
| 2019 Q2 | -58.56 Thousand CAD | 10.51% |
| 2018 Q4 | -130.28 Thousand CAD | -321.14% |
| 2018 Q3 | -30.93 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.0% |
| GB Sciences, Inc. | -1.41 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.0% |
| Zenith Capital Corp. | -8.6 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.0% |
| Biomind Labs Inc. | -1.03 Million USD | 100.0% |
| ContraFect Corporation | -64.99 Million USD | 100.0% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| CytoDyn Inc. | -18.02 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 100.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.0% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.0% |
| Mesoblast Limited | -62.38 Million USD | 100.0% |
| Marizyme, Inc. | -34.28 Million USD | 100.0% |
| Genus plc | 73.7 Million USD | 100.0% |
| Pharming Group N.V. | 9.87 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.0% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| IMV Inc. | -35.52 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 100.0% |
| ONE Bio Corp. | 13.61 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| Enzolytics Inc. | -2.12 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -216.02 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.0% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 100.0% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.0% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 100.0% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.0% |
| HST Global, Inc. | -5303.00 USD | 100.0% |
| Burzynski Research Institute, Inc. | - USD | NaN% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 100.0% |
| Resverlogix Corp. | -11.74 Million USD | 100.0% |
| Cell Source, Inc. | -4.27 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| NovAccess Global Inc. | -1.03 Million USD | 100.0% |
| Kadimastem Ltd | -2.62 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100.0% |
| LadRx Corporation | 412.28 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.0% |
| Affymax, Inc. | -14.29 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Mobile Lads Corp. | -2.24 Million USD | 100.0% |
| International Stem Cell Corporation | 202 Thousand USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 100.0% |
| Qrons Inc. | -40.08 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 100.0% |
| SYBLEU INC | -141.57 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -35.86 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | - USD | NaN% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -45 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.0% |
| Neutra Corp. | -181.24 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| PureTech Health plc | -11.62 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| IXICO plc | -707 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.0% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.0% |